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Abstract 
Inhibition of immune checkpoints Programmed Death 1 (PD-1) and Cytotoxic T-lymphocyte 
Associated Protein 4 (CTLA-4) on T cells results in durable anti-tumor activity in melanoma 
patients. Despite high frequency of melanoma brain metastases (BrM) and associated poor 
prognosis, the activity and mechanisms of immune checkpoint inhibitors (ICI) in metastatic tumors 
WKDW GHYHORS ZLWKLQ WKH ³LPPXQH VSHFLDOL]HG´ EUDLQ PLFURHQYLURQPHQW UHPDLQ HOXVLYH :H
established a melanoma tumor transplantation model with intracranial plus extracranial 
(subcutaneous) tumor, mimicking the clinically observed coexistence of metastases inside and 
outside the brain. Strikingly, intracranial ICI efficacy was observed only when extracranial tumor 
was present. Extracranial tumor was also required for ICI-induced increase in CD8+ T cells, 
macrophages and microglia in brain tumors, as well as for upregulation of immune-regulatory 
genes. Combined PD-1/CTLA-4 blockade had a superior intracranial efficacy over the two 
monotherapies. Cell depletion studies revealed that NK cells and CD8+ T cells were required for 
intracranial anti-PD-1/anti-CTLA-4 efficacy. Rather than enhancing CD8+ T cell activation and 
expansion within intracranial tumors, PD-1/CTLA-4 blockade dramatically (~14-fold) increased 
the trafficking of CD8+ T cells to the brain. This was mainly through the peripheral expansion of 
homing-competent effector CD8+ T cells and potentially further enhanced through upregulation 
of T cell entry receptors ICAM-1 and VCAM-1 on tumor vasculature. Our study indicates that 
extracranial activation/release of CD8+ T cells from PD-1/CTLA-4 inhibition and potentiation of 
their recruitment to the brain are paramount to the intracranial anti-PD-1/anti-CTLA-4 activity, 
suggesting augmentation of these processes as an immune therapy-enhancing strategy in metastatic 
brain cancer.  
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Significance statement: 
Brain metastases are an unmet clinical need with high frequency in melanoma patients. With 
immune checkpoint inhibitors targeting PD-1 and CTLA-4 becoming a frontline therapy in 
PHODQRPDLWLVFULWLFDOWRXQGHUVWDQGKRZWKLVWKHUDS\ZRUNVLQWKH³LPPXQH-VSHFLDOL]HG´EUDLQ
microenvironment. Our study shows that in the absence of extracranial tumor, melanoma tumors 
growing in the brain escape anti-PD-1/anti-CTLA-4 therapy. A synergy between immune 
checkpoint inhibition and extracranial tumor is required to put a break on brain metastases by 
enhancing CD8+ T cell recruitment to the brain via peripheral expansion of effector cells and 
upregulation of T cell entry receptors on tumor blood vessels. Augmentation of these processes 
could be explored to enhance the efficacy of immunotherapy in brain metastases. 
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³\ERG\´ 
Introduction 
Brain metastases (BrM) are an unmet clinical need with very limited treatment options and poor 
prognosis. Metastatic melanoma has the highest risk of spreading to the central nervous system 
(CNS) among common cancers; up to a quarter of patients have BrM at metastatic diagnosis, and 
the incidence at autopsy is up to ~75% (1-3). Until recently, treatment options for melanoma BrM 
have been restricted to radiotherapy, surgery, and targeted therapies, with the median overall 
survival below one year (4, 5). In recent years, cancer treatment has been revolutionized by 
immunotherapy targeting PD-1 and CTLA-4 immune-inhibitory receptors (immune checkpoints) 
expressed mainly on T cells. Function-blocking antibodies against CTLA-4 (ipilimumab) and PD-
1 (nivolumab, pembrolizumab) enhance anti-tumor T cell responses and result in durable anti-
tumor activity across most cancers (6, 7). In melanoma, the anti-PD-1/anti-CTLA-4 combination 
therapy showed a superior efficacy as compared to the two monotherapies (8), and has been 
approved in various countries (9). Despite numerous studies on anti-PD-1 and anti-CTLA-4 in 
melanoma, very limited data are available for BrM, mainly due to frequent exclusion of patients 
with BrM from clinical trials (4, 10). A handful of retrospective and prospective clinical studies 
indicated activity of ipilimumab in melanoma BrM with 16-25% intracranial response rate, but 
also suggested that only a subgroup of patients is likely to benefit (4, 5, 11). Pembrolizumab and 
nivolumab also showed efficacy in melanoma BrM with an ~21% response rate in the brain (12-
15). A very recent interim analyses from two clinical trials in drug-treatment naïve patients with 
melanoma BrM (ABC trial (15) and CheckMate 204 trial (16)) reported a 50% and 55% 
intracranial response rate following combined anti-PD-1 plus anti-CTLA-4 therapy. 
In addition to limited clinical data, there is a complete lack of preclinical data on anti-PD-1 
and anti-CTLA-4 therapy in melanoma BrM. Preclinical studies in BrM are hampered by the lack 
of melanoma models that can recapitulate clinically observed metastatic patterns and coexistence 
of metastases in different organs. Spontaneous metastasis to the brain in preclinical models is a 
rare event and macroscopic BrM are usually not observed (17). Only two immunocompetent pre-
clinical melanoma models of spontaneous BrM have been reported (18, 19), but analysis of BrM-
specific survival in therapeutic studies remains a challenge due to a faster development of 
extracranial as compared to intracranial metastases.  
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Notably, differences in regulation of adaptive T cell responses to antigens located in the CNS 
as compared to antigens outside the CNS have been well documented (20-24). Due to this 
GLIIHUHQFHLQDGDSWLYHLPPXQHUHVSRQVHVWKH&16KDVEHHQUHIHUUHGWRDV³LPPXQHVSHFLDOL]HG´
Moreover, the phenotype of immune cells infiltrating brain metastases has been shown to be 
altered by inflammatory molecules upregulated specifically in cancer cells growing in the brain 
parenchyma (25). Hence, with immune checkpoint inhibitors (ICI) now being frontline therapy for 
metastatic melanoma, the question arises as to what extent the metastatic tumors residing within 
the immune specialized brain microenvironment respond to ICI. Moreover, the requirements for 
effective anti-PD-1/anti-CTLA-4 therapy in the brain remain to be identified. 
To address the above knowledge gaps and study anti-PD-1/anti-CTLA-4-dependent survival 
and mechanisms specifically in BrM while simulating the clinically observed coexistence of 
metastasis in the skin (the most common metastatic site (26)), we established a melanoma 
transplantation model with extracranial (subcutaneous) plus intracranial tumors, in which the 
overall survival depends on the intracranial tumor growth. In addition to demonstrating a superior 
intracranial efficacy of combined PD-1/CTLA-4 blockade over the two monotherapies, we made 
a striking observation that anti-PD-1/anti-CTLA-4 activity in the brain depends on the presence of 
extracranial tumor, highlighting the importance of mimicking clinically observed extracranial 
disease in the context of ICI studies. We further show that the intracranial activity of anti-PD-
1/anti-CTLA-4 therapy requires the augmentation of CD8+ T cell trafficking to the brain and we 
analyze the underlying mechanisms. 
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Results  
The presence of extracranial tumor is critical for intracranial anti-PD-1/anti-CTLA-4 
efficacy 
The vast majority of BrM in melanoma coincide with metastases outside the brain, predominantly 
in the skin (26). To mimic this clinical situation, we established a tumor transplantation model of 
B16 melanoma with extracranial (subcutaneous) plus intracranial tumors. To identify the optimal 
experimental timeline allowing us to study survival specifically in dependence of intracranial 
tumor growth, we first determined tumor growth kinetics and survival times in mice bearing either 
extracranial or intracranial tumors (Fig. 1A; Supplemental Fig. 1A, B). The mean survival time 
for mice with intracranial tumors was 10.8r1.5 days. Extracranial tumors reached the maximum 
allowable diameter of 15 mm on day 16.5r1.4 and none of the mice showed terminal symptoms 
at this time point. Thus, subcutaneous (s.c.) implantation of cancer cells into the flank 3 days prior 
to their intracranial implantation (Fig. 1B) allowed for quantification of the intracranial tumor-
dependent survival. 
Following administration of 4 doses of either anti-CTLA-4 or anti-PD-1 antibody 
monotherapy (Fig. 1B), the overall survival of mice in this model was only marginally and non-
significantly extended as compared to control mice receiving IgG isotype antibody (Fig. 1C, 
Supplemental Fig. 1C). In contrast to monotherapies, the anti-PD-1/anti-CTLA-4 combination 
significantly prolonged survival in our model and inhibited intracranial as well as extracranial 
tumor growth (Fig. 1C-E, Supplemental Fig. 1C). Thus, the outcome of anti-PD-1/anti-CTLA-4 
combination therapy was superior to the two monotherapies, which is in line with the reported 
intracranial response rate for anti-PD-1 monotherapy (21-25%) (12-15) and anti-PD-1/anti-CTLA-
4 combination therapy (50-55%) (15, 16), as well as the 6 month progression-free survival rate of 
28% and 46%, respectively (15). Due to these promising data, we focused on the anti-PD-1/anti-
CTLA-4 combination therapy. 
To validate the relevance of extracranial disease in the context of anti-PD-1/anti-CTLA-4 
therapy for BrM, we compared therapeutic efficacy between mice bearing intracranial tumors only 
(representing a conventional intracranial tumor transplantation model (17, 27)), and mice bearing 
tumors at both sites. Strikingly, in the absence of extracranial disease, the anti-PD-1/anti-CTLA-4 
combination failed to extend the survival or to reduce the intracranial tumor burden (Fig. 1F-H, 
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Supplemental Fig. 1D-E). This observation reproduced in a B16 model overexpressing an 
immunogenic ovalbumin (OVA) xenoantigen (28), hence demonstrating that increasing the 
inherent immunogenicity of the model is not sufficient to induce anti-tumor responses in the brain 
following PD-1/CTLA-4 blockade (Fig. 1I). The requirement of extracranial disease for 
intracranial anti-PD-1/anti-CTLA-4 efficacy was further confirmed in the Ret melanoma model 
(19, 29), demonstrating that our findings are model-independent (Fig. 1J; see Supplemental Fig. 
1F-H for the establishment of experimental timeline in Ret model). Taken together, our results 
reveal that the intracranial activity of anti-PD-/anti-CTLA-4 depends on the extracranial tumor, 
highlighting the importance of including the clinically-relevant extracranial disease in this context. 
 
Immune response in the brain is enhanced in the presence of extracranial disease 
To evaluate the immunological response in the brain upon anti-PD-1/anti-CTLA-4 therapy and the 
role of extracranial disease, we analyzed the tumor-infiltrating immune cells in intracranial B16 
tumors by flow cytometry (Supplemental Fig. 2A). Although anti-PD-1/anti-CTLA-4 therapy 
resulted in a small increase in intra-tumoral CD45+ cells in the absence of extracranial disease, a 
major anti-PD-1/anti-CTLA-4-induced increase in this cell population, and significant expansion 
of CD3+ T cells, were observed only in the presence of s.c. tumor (Fig. 2A, B, C, Supplemental 
Fig. 2B). Likewise, anti-PD-1/anti-CTLA-4-induced increases in CD8+ T cells (Fig. 2D), 
CD11b+F4/80+CD45high (25, 30, 31) bone marrow-derived macrophages (Fig. 2G), and 
CD11b+F4/80+CD45low (25, 30, 31) brain-resident microglia (Fig. 2H) were detected only in the 
presence of extracranial disease. In contrast, the percentages of total CD4+ T cells, FoxP3+CD4+ 
regulatory T cells (Treg) and FoxP3-CD4+ effector T cells (Teff) increased upon anti-PD-1/anti-
CTLA-4 treatment independent of extracranial tumor (Fig. 2D). The CD4+Teff / Treg ratio, the 
increase of which was previously associated with therapeutic efficacy in some studies (32), 
remained unaltered (Fig. 2E). The proportion of NK cells also remained unchanged (Fig. 2F). 
Importantly, similar changes in immune cell populations within intracranial tumors were observed 
in the Ret melanoma model (Supplemental Fig. 3A). 
To determine whether monotherapies are sufficient to induce infiltration of immune cells into 
intracranial tumors, we analyzed immune cell populations in mice bearing intracranial and 
extracranial B16 tumors, following anti-PD-1 or anti-CTLA-4 monotherapy. Both monotherapies 
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failed to increase the proportion of immune cells in intracranial tumors as compared to IgG-treated 
mice (Supplemental Fig. 3B). Thus, the lack of therapeutic efficacy observed for the two 
monotherapies was in line with their failure to induce immune cell infiltration into intracranial 
tumors. 
To evaluate the immunological response in the brain at the molecular level, intracranial B16 
tumors were profiled using next generation RNA sequencing (mRNAseq). Differential gene 
expression analysis (adjusted p value < 0.05) indicated that the presence of extracranial disease 
did not cause any significant alterations in gene expression levels in IgG-treated control mice (Fig. 
3A). In contrast, the presence of extracranial disease resulted in altered expression of 4154 genes 
in anti-PD-1/anti-CTLA-4-treated mice. This suggested that extracranial disease has significant 
impact on the intracranial tumor only in the context of PD-1/CTLA-4 blockade. In contrast, anti-
PD-1/anti-CTLA-4 therapy itself had impact on gene expression both in the absence (906 
differentially expressed genes) and presence (621 differentially expressed genes) of extracranial 
disease. Importantly, brain tumors from mice with intracranial and extracranial tumors undergoing 
anti-PD-1/anti-CTLA-4 treatment had significantly distinct transcriptomes as compared to the 
other 3 experimental groups (Fig. 3B). Gene ontology (GO) enrichment analysis identified classes 
of genes significantly altered upon anti-PD-1/anti-CTLA-4 therapy in the presence of extracranial 
disease, revealing significant upregulation in GO terms relating to NK cell activation and 
chemotaxis (Fig. 3C), T cell activation (Fig. 3D, Supplemental Fig. 4A), and 
microglia/macrophage activation and migration (Fig. 2E, Supplemental Fig. 4B).  
Hence, our data revealed that anti-PD-1/anti-CTLA-4 efficacy in the brain correlates with 
intra-tumoral increase in CD8+ T cells, macrophages and microglia, as well as upregulation of 
genes involved in activation of T cells, NK cells, and microglia/macrophages. This implies that 
anti-PD-1/anti-CTLA-4 activity relies on multiple immune cell populations, the activation and/or 
intra-tumoral increase of which were dependent on the presence of extracranial tumor. 
 
CD8+ T cells and NK cells are required for the intracranial efficacy of anti-PD-1/anti-CTLA-
4 therapy 
The upregulation of T cell and NK cell activation markers in association with the intracranial anti-
PD-1/anti-CTLA-4 efficacy prompted us to investigate the functional role of these cell populations 
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in the context of PD-1/CTLA-4 blockade. Antibody-mediated depletion of NK cells, CD4+ or 
CD8+ T cells was performed in mice bearing intracranial and extracranial B16 tumors undergoing 
anti-PD-1/anti-CTLA-4 therapy (Fig. 4A). Efficient depletion of respective cell populations in the 
blood and tumor tissue was confirmed by flow cytometry (Supplemental Fig. 5). While the 
depletion of CD4+ T cells had no impact on survival (Fig. 4B), depletion of either NK (Fig. 4C) 
or CD8+ T cells (Fig. 4D) resulted in a significant loss of survival advantage observed upon anti-
PD-1/anti-CTLA-4 therapy, demonstrating a critical involvement of these cell populations. 
To further characterize T cells in intracranial B16 tumors, we analyzed the expression of 
known T cell activation/exhaustion markers (e.g. CD25, CD69, Granzyme B, Eomesodermin 
(EOMES), T-cell immunoglobulin and mucin domain containing-3 (TIM3)) in CD4+ and CD8+ 
T cells by flow cytometry (Supplemental Fig. 6A). We detected no changes in the percentages of 
cells expressing the investigated markers or in their protein expression levels (mean fluorescence 
intensity; MFI) (Supplemental Fig. 6B, C). Therefore, marked increase in the overall gene 
expression levels of T cell activation markers following anti-PD-1/anti-CTLA-4 therapy in the 
presence of extracranial tumor (Fig. 3D) can be explained by the increased intra-tumoral 
percentage of CD8+ T cells (Fig. 2D). Our findings thus imply that inhibition of intracranial tumor 
growth was caused by an increase in CD8+ T cell numbers rather than their enhanced intra-tumoral 
activation. 
 
Anti-PD-1/anti-CTLA-4 treatment enhances trafficking of CD8+ T cells to intracranial 
tumors 
We next sought to determine the underlying mechanism for the increase in intra-tumoral CD8+ T 
cells following anti-PD-1/anti-CTLA-4 therapy. The proportion of proliferative CD8+ T cells 
within intracranial B16 tumors was high (~75% Ki67+ cells) and remained unaffected by anti-PD-
1/anti-CTLA-4 treatment or the presence of extracranial disease (Fig. 5A). This finding excluded 
intra-tumoral expansion of CD8+ T cells as a major driver of their intra-tumoral increase. We 
therefore reasoned that enhanced recruitment of CD8+ T cells from outside the brain is likely 
responsible for their accumulation in intracranial tumors following PD-1/CTLA-4 blockade. To 
investigate this, we analyzed the trafficking of CD8+ T cells to intracranial tumors by performing 
an adoptive transfer of CellTrace Violet (CTV)-labeled CD8+ T cells (4x106) in mice with 
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extracranial plus intracranial tumors. T cell donor and recipient mice both received 2 doses of anti-
PD-1/anti-CTLA-4 or IgG (Fig. 5B), which was sufficient to significantly increase the overall 
percentage of intra-tumoral CD8+ T cells in treated as compared to control mice (Supplemental 
Fig. 8A). CD8+ T cells from IgG-treated donor mice were transferred into IgG-treated recipient 
mice, and cells from anti-PD-1/anti-CTLA-4-treated donor mice were transferred into anti-PD-
1/anti-CTLA-4-treated recipient mice (Fig. 5B). Analysis of intra-tumoral CTV+ CD8+ T cells at 
18 hours post-adoptive transfer demonstrated a strong increase (~14-fold) in CD8+ T cell homing 
to intracranial tumors in the presence of anti-PD-1/anti-CTLA-4 therapy (Fig. 5C, D). Notably, 
we observed no significant proliferation of adoptively transferred T cells within 18 hours, and 
therefore increase in intra-tumoral CTV+ CD8+ T cells was attributable exclusively to their 
trafficking and not their proliferation (Supplemental Fig. 8B). 
To investigate whether systemic T cell expansion may contribute to enhanced accumulation 
of CD8+ T cells in intracranial B16 tumors, we analyzed peripheral T cell populations in the blood 
and spleens. All anti-PD-1/anti-CTLA-4-dependent changes in ratios of peripheral CD8+ T cells, 
CD4+ Teff and Treg cells occurred independently of extracranial disease (Supplemental Fig. 7A, 
B). In contrast, PD-1/CTLA-4 blockade-induced increase in CD44+CD62L- effector CD8+ T cells 
in blood was significantly enhanced in the presence of extracranial disease, and thus correlated 
with the intracranial anti-PD-1/anti-CTLA-4 efficacy (Fig. 5E). Analysis of intracranial tumors 
revealed that the majority of intra-tumoral CD8+ T cells were CD44+CD62L- effector cells in 
both treated and control mice (Fig. 5F). This prompted us to compare homing of CD44+CD62L- 
effector and CD44-CD62L+ naïve CD8+ T cells to intracranial tumors. Notably, the percentage of 
CD8+ T cells within pooled spleen and lymph nodes was slightly higher in anti-PD-1/anti-CTLA-
4 treated mice (10.3%) as compared to the IgG treated mice (9%) (Fig. 5G, top). Moreover, the 
percentage of CD44+CD62L- cells within CD8+ T cell population was higher in anti-PD-1/anti-
CTLA-4 treated mice (3.8%) as compared to IgG treated mice (2.2%) (Fig. 5G, bottom). Thus, to 
ensure that the same numbers of cells per investigated CD8+ T cell population are used for 
adoptive transfer in the control and therapy group, we sorted CD44+CD62L- and CD44-CD62L+ 
CD8+ T cell populations from pooled spleens and lymph nodes of IgG- and anti-PD-1/anti-CTLA-
4-treated mice, respectively. CTV-labeled CD44+CD62L- (1x105) and CD44-CD62L+ (2.4x106) 
cells, respectively, were transferred into recipient mice that received the corresponding treatment 
(Fig. 5D). Analysis of CTV+ CD8+ T cells within intracranial tumors at 18 hours post-transfer 
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confirmed that only CD44+CD62L- cells efficiently homed to intracranial tumors (Fig. 5H). 
Notably, we detected a tendency towards more efficient homing of CD44+CD62L- CD8+ T cells 
isolated from anti-PD-1/anti-CTLA-4-treated mice (0.009±0.004% all cells) as compared to the 
IgG control mice (0.006±0.002% all cells; Fig. 5I). In summary, this suggested that an enhanced 
homing of CD8+ T cells to intracranial tumors following anti-PD-1/anti-CTLA-4 therapy is mainly 
due to the peripheral expansion of CD44+CD62L- effector cells. However, a tendency towards 
more efficient homing of effector CD8+ T cells isolated from anti-PD-1/anti-CTLA-4-treated mice 
as compared to IgG-treated mice implied that additional factors may be involved. 
 
PD-1/CTLA-4 blockade upregulates T cell trafficking determinants on tumor blood vessels 
Consistent with a tendency towards increased trafficking of CD8+ effector T cells to intracranial 
tumors following anti-PD-1/anti-CTLA-4 treatment, KEGG pathway analysis identified 
³/HXNRF\WH WUDQVHQGRWKHOLDO PLJUDWLRQ´ DV RQH RI WKH SDWKZD\V VLJQLILFDQWO\ XSUHJXODWHG LQ
intracranial tumors following PD-1/CTLA-4 blockade in the presence of extracranial disease as 
compared to the other 3 experimental groups (Fig. 6A). Among the upregulated genes, Vascular 
cell adhesion molecule 1 (VCAM-1) and Intercellular adhesion molecule 1 (ICAM-1) - two major 
endothelial T cell entry receptors (33) - were upregulated 6.4- and 3.8-fold, respectively (Fig. 6A). 
VCAM-1 expression on tumor blood vessels was confirmed by immunofluorescence (Fig. 6B). 
Analysis of VCAM-1 and ICAM-1 expression on tumor endothelial cells by flow cytometry 
confirmed a significant upregulation of both receptors following anti-PD-1/anti-CTLA-4 therapy 
in the presence of extracranial disease (Fig. 6C, D, Supplemental Fig. 8C). The percentage of 
ICAM-1+ endothelial cells increased from ~75 to 90% and the percentage of VCAM-1+ 
endothelial cells from ~5 to 45%. Moreover, the expression levels of both receptors were ~3-fold 
elevated, as indicated by a significant increase in MFI (Fig. 6D). 
Following anti-PD-1/anti-CTLA-4 therapy, blood vessels within the tumor-adjacent brain 
parenchyma remained negative for VCAM-1 expression (Supplemental Fig. 8D), indicating that 
the upregulation of T cell entry receptors was restricted to the tumor microenvironment. In line 
ZLWKWKLVILQGLQJJHQHH[SUHVVLRQOHYHOVRI,)1Ȗ± a known inducer of endothelial VCAM-1 and 
ICAM-1 (33) ± were upregulated within intracranial tumors following anti-PD-1/anti-CTLA-4 
therapy in mice bearing tumors at both sites (Supplemental Fig. 8E). Concurrently, intracellular 
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IORZF\WRPHWU\VWDLQLQJUHYHDOHGDVLJQLILFDQWLQFUHDVHLQWKHSHUFHQWDJHRI,)1ȖFHOOVZLWKLQ1.
cell and macrophage populations (Fig. 6E, top ZKLOH 71)Į H[SUHVVLRQ UHPDLQHG XQDOWHUHG
(Supplemental Fig. 8F). Although such an increase in ,)1ȖH[SUHVVLRQZDVQRWGHWHFWHGIRU&'
T cells and microglia, their increased proportion within intracranial tumors per se also contributed 
WRZDUGVDQRYHUDOOLQFUHDVHLQ,)1ȖFig. 6E, bottom). 
In summary, our data indicate that anti-PD-1/anti-CTLA-4 treatment ± in the context of 
clinically relevant extracranial disease ± increases intra-tumoral CD8+ T cells in the brain through 
peripheral expansion of CD44+CD62L- effector CD8+ T cells and potentiation of their trafficking 
to intracranial tumors, the latter potentially occurring via upregulation of T cell entry receptors 
ICAM1/VCAM1 on the tumor vasculature. 
 
  
13 
 
Discussion  
In this study we reveal that extracranial disease plays a critical role for the intracranial efficacy of 
combined anti-PD-1 plus anti-CTLA-4 therapy. This was demonstrated through analysis of 
intracranial tumor-dependent survival, quantification of tumor growth, characterization of tumor-
infiltrating immune cell populations, and gene expression analysis (mRNAseq). Importantly, 
clinically observed intracranial activity of anti-PD-1/anti-CTLA-4 therapy (4, 5, 11-15) could be 
recapitulated only in the tumor transplantation model with intracranial plus extracranial tumor, but 
not in the model bearing only intracranial cancer lesions, which is a conventional brain tumor 
transplantation model (17, 27). Moreover, superior intracranial activity of anti-PD-1/anti-CTLA-
4 combination therapy in our optimized model was in line with the  reported higher intracranial 
response rates with combined anti-PD-1 plus anti-CTLA-4 (50%) than anti-PD-1 alone (21%) in 
drug-treatment naïve patients (15). Thus, by including extracranial tumor, we achieved an 
important improvement in simulating human disease and clinical responses to PD-1 and CTLA-4 
blockade in the brain, and thus our model is expected to significantly advance preclinical studies 
on immunotherapy in BrM. 
In terms of adaptive immune responses, the brain is markedly different from other major sites 
of metastasis, such as the skin, lungs and bones (26). While antigens from these other sites are 
efficiently transported to the peripheral lymphoid organs where T cell priming/activation occurs, 
a body of literature shows that antigens located within the brain are less accessible and transported 
to lymph nodes at a different location (e.g. cervical lymph nodes), and/or presented in a different 
way (20-23). In line with this notion, our study reveals that successful targeting of melanoma BrM 
with anti-PD-1/anti-CTLA-4 antibodies relies on: (i) tumor antigens present at extracranial 
locations and (ii) release of CD8+ T cells from immune checkpoint inhibition and their activation 
occurring outside the brain. Notably, release of T cells from immune checkpoint inhibition and 
their subsequent increased proliferation following anti-CTLA-4 and anti-PD-1 therapy is mainly 
observed within secondary lymphoid organs and within the tumor microenvironment, respectively 
(14). Accordingly, increase in proliferation of intra-tumoral CD8+ T cells occurs in s.c. B16 
melanoma tumors following PD-1 blockade alone or in combination with anti-CTLA-4 or 
radiotherapy (34-36). However, in contrast to extracranial sites, the blood-brain barrier limits 
access of therapeutic antibodies into brain tumors, which may preclude anti-PD-1-induced release 
of T cells from proliferation block once they have entered the brain tumor microenvironment. 
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Indeed, in our study, anti-PD-1/anti-CTLA-4 combination failed to increase the proportion of 
proliferative CD8+ T cells and their expression of activation markers within intracranial tumors. 
This provides strong evidence that the release of CD8+ T cells from immune checkpoint inhibition 
occurred mainly outside the brain, and that intracranial anti-PD-1/anti-CTLA-4 activity relies on 
the subsequent recruitment of these extracranially activated CD8+ T cells to intracranial tumors. 
Our data suggest that enhanced CD8+ T cell trafficking to intracranial tumors following anti-
PD-1/anti-CTLA-4 therapy in the context of extracranial disease may be enhanced through the 
upregulation of VCAM-1 and ICAM-RQWXPRUEORRGYHVVHOV,)1ȖZDVLGHQWLILHGDVRQHRIWKH
potential factors involved in the upregulation of these vascular receptors. NK cells and 
microglia/macrophages were the main source of anti-PD-1/anti-CTLA-4-LQGXFHG ,)1Ȗ
upregulation. This finding may explain why intracranial anti-PD-1/anti-CTLA-4 efficacy required 
NK cells and correlated with intra-tumoral increase in macrophages. Notably, the latter may have 
been recruited to intracranial tumors through colony stimulating factor 1 (CSF-1), a potent 
microglia/macrophages chemoattractant (37) which, in our study, was found to be upregulated 2.8-
fold following anti-PD-1/anti-CTLA-4 therapy in the presence of extracranial tumor. Several 
VWXGLHVUHSRUWHG,)1ȖLQFUHDVHLQWXPRUVIROORZLQJ,&,WUHDWPHQWDOWKRXJKWKLVKDVQRW\HWEHHQ
connected to the upregulation of vascular T cell homing determinants or enhanced T cell 
trafficking (34, 36, 38)1HYHUWKHOHVV,)1Ȗ-dependent upregulation of ICAM-1 on choroid plexus 
epithelial cells in the brain has been recently shown to increase T cell infiltration into the brain in 
PRGHOVRIVSLQDOFRUGLQMXU\DQG$O]KHLPHU¶VGLVHDVH(39, 40). 
More than half of patients with metastatic melanoma develop BrM and, with ICI becoming 
the frontline therapy for metastatic disease, it is critical to understand how immune checkpoint 
inhibition can be optimized in the brain. Since the intracranial anti-PD-1/anti-CTLA-4 efficacy 
seemed to rely on the recruitment of activated CD8+ T cells from outside the brain, strategies 
aimed at enhancing T cell homing - for example through adoptive T cell therapy using T cells with 
enhanced BrM-homing characteristics - have a strong potential to improve the efficacy of ICI in 
the brain. Moreover, our findings on the critical role of extracranial disease for intracranial anti-
PD-1/anti-CTLA-4 efficacy are of relevance to the optimization of ICI for primary non-metastatic 
brain cancers, in particular glioma. Notably, in contrast to clinical evidence for anti-PD-1 activity 
in melanoma BrM (12, 13), a recent phase III clinical trial of nivolumab in glioma was negative 
(https://news.bms.com/press-release/bmy/bristol-myers-squibb-announces-results-checkmate-
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143-phase-3-study-opdivo-nivoluma). Our data suggest that the combination of ICI with strategies 
that boost the peripheral antigen-specific T cell activation, such as cancer vaccines, may also 
improve anti-PD-1/anti-CTLA-4 efficacy in metastatic and non-metastatic brain cancers. 
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Materials and Methods 
 
In vivo model of brain metastases 
All procedures were approved by the University of Leeds Animal Welfare & Ethical Review 
Committee and performed under the approved UK Home Office project license in line with the 
Animal (Scientific Procedures) Act 1986 and in accordance with the UK National Cancer Research 
Institute Guidelines for the welfare of animals (41). 
Six to eight weeks old female C57Bl/6J or B6N-Tyrc-Brd/BrdCrCrl (B6 Albino) mice were 
purchased from Charles River Laboratories, UK. B16 F1, B16/OVA or Ret melanoma cells (please 
refer to Supplementary methods for cell line details) were injected s.c. on the flank to generate 
extracranial tumors (2×105 B16 and B16/OVA cells; 1×105 Ret cells). To generate intracranial 
tumors, cancer cells (1×105 B16/Fluc and B16/OVA/Fluc cells; 1x103 Ret/Fluc cells) were 
stereotactically injected into the striatum (2 mm right from the midline, 2 mm anterior from 
bregma, 3 mm deep). Prior to treatment, mice used in experiments with B16 and B16/OVA models 
were randomized into groups based on the intracranial bioluminescence signals ensuring equal 
distribution of tumor burden across groups. Mice used in experiments with the Ret melanoma 
model were randomized into groups so as to ensure an equal proportion of mice from different 
litters per group (randomization based on the bioluminescence signal intensity was not possible at 
early time points due to the low number of implanted cells in this model). Anti-PD-1 (RMP1-14), 
anti-CTLA-4 (9D9) and IgG control (MPC11) purchased from Bio-X-Cell were administered i.p. 
at 200 µg per mouse as indicated. 
Experimental group sizes were determined with power analysis (power = 80%, significance 
level = 5%, difference to be detected between groups = 50%) using the mean values and standard 
deviations from our pilot studies. All animals were included in the survival analysis and tumor 
growth analysis. In cases where tumors were too small to obtain sufficient material for facs 
analysis, the animals were excluded from this analysis. All outliers were included in the analysis. 
The study was not blinded. 
Quantification of extracranial tumor growth was performed by caliper measurement. 
Quantification of intracranial tumor growth was performed via non-invasive bioluminescence 
imaging using IVIS Spectrum and Living Image software (PerkinElmer). 
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Immune cell depletion was achieved through i.p. administration of anti-CD8Į (YTS.4; Bio-
X-Cell), anti-CD4 (GK1.5; Bio-X-Cell), or anti-asialo-GM1 that depletes NK cells (polyclonal 
rabbit IgG; Cedarlane) at 100 µg per mouse every 4 days. For GHWHFWLRQRI,)1ȖDQG71)ĮE\IORZ
F\WRPHWU\ PLFH UHFHLYHG  ȝJ %UHIHOGLQ $ 6LJPD LY  KRurs prior to tissue harvesting. 
Adoptive T cell trabnsfer experiments are described under Supplementary methods. 
 
Immunofluorescence 
Immunofluorescence was performed as previously described (25). Details are provided under 
Supplementary methods. 
 
Flow cytometry 
Mice were perfused with saline. Tumors were mechanically disrupted and enzymatically 
dissociated (25). The blood (collected from tail vein) and splenocytes were treated with 
ammonium-chloride-potassium buffer to lyse red blood cells. Samples were blocked with 10% rat 
serum and FcR blocking reagent (Miltenyi) prior to surface antigen staining. FoxP3/Transcription 
Factor Staining Buffer Set (eBioscience) was used for intracellular staining of nuclear antigens 
IROORZLQJ PDQXIDFWXUHU¶V LQVWUXFWLRQV ,QWUDFHOOXODU IL[DWLRQ EXIIHU DQG 3HUPHDELOL]DWLRQ EXIIHU
(eBioscience) weUH XVHG IRU VWDLQLQJ RI F\WRSODVPLF DQWLJHQV IROORZLQJ PDQXIDFWXUHU¶V
instructions. Cells were analyzed on BD LSRII Flow Cytometry Analyzer (Life Technologies). 
Data were quantified using FACSDiva software. The gates were set based on appropriate isotype 
controls. Antibody details are provided in Supplementary methods. 
 
RNAseq and gene expression analysis 
Details are provided under Supplementary methods. 
 
Statistical analysis 
Statistical analysis was carried out using Graph Pad Prism v7 (Graph Pad Software). Statistical 
tests used were analysis of variance (ANOVA) with a post hoc test for multiple comparisons 
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7XNH\¶VPXOWLSOHFRPSDULVRQVWHVW, Mann-Whitney test and Mann-Whitney U Test, as specified 
in figure legends. All tests except the Mann-Whitney U Test were 2-tailed statistical tests. 
Statistical significance in survival experiments was determined with Log-rank test. Error bars 
represent standard error of the mean (SE), except in Fig. 6E where the bars represent standard 
deviations. The number of biological replicates for each experiment is stated in figure legends. 
Each experiment was performed 2-4 times, as specified. Data from repeat experiments were 
combined as indicated in figure legends. 
 
Data availability statement 
Gene expression data (mRNAseq) will be deposited in an approved database prior to publication.  
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Figure legends 
 
Fig. 1. Inhibition of intracranial tumor growth and prolonged survival following anti-PD-
1/CTLA-4 therapy require the presence of extracranial disease. (A) Survival of C57Bl/6J mice 
following intracranial implantation of B16/Fluc melanoma cells (n=8) and time to the 
establishment of extracranial B16 s.c. tumors with a diameter of 15 mm (n=10). (B) Experimental 
time line for the implantation of cancer cells in B16 model and therapeutic schedule. (C) Survival 
of mice with intracranial (B16/Fluc) plus extracranial (B16) tumors following the administration 
of anti-PD-1, anti-CTLA-4, anti-PD-1/CTLA-4, or IgG control (n=8). The overall significance is 
shown. Individual p values are given in Fig. S1C. (D) Quantification of intracranial B16/Fluc 
tumor burden via bioluminescence imaging (n=20/24). Fold change in bioluminescence signal 
intensity between days 12 and 5 (e.g. pre/post-treatment) for mice treated with anti-PD-1/CTLA-
4 or IgG. (E) Quantification of extracranial B16 tumor burden on day 12 via caliper measurement 
(n=20/24). (F) Survival following anti-PD-1/anti-CTLA-4 or IgG administration was compared 
between mice bearing only intracranial B16/Fluc tumors and mice bearing intracranial B16/Fluc 
and extracranial B16 tumors. The overall significance is indicated. Individual p values are 
summarized in Fig. S1D. (G)  Representative images of intracranial bioluminescence signals 
(B16/Fluc tumors). (H, I) Fold change in intracranial bioluminescence signal intensity between 
days 12 and 5 (e.g. pre/post-treatment) for the B16/Fluc (H) and B16/OVA/Fluc (I) melanoma 
models (n=21/21/20/24 for B16/Fluc; n=16/16/15/25 for B16/OVA/Fluc). Labeling as in F. (J) 
Quantification of intracranial Ret/Fluc melanoma burden (n=8/8/8/13). Bioluminescence signal 
intensity (total flux; photons/second) is shown. Labeling as in F. Significant differences in C and 
F were determined with Log-rank test. Significant differences in D, E, H, I and J were determined 
with Mann-:KLWQH\ WHVW  S  S  S). Data from 2 (I) or 3 (C-F, H) 
independent experiments are shown. 
 
Fig. 2. Analysis of immune cell populations in intracranial B16 tumors reveals extracranial 
tumor- and PD-1/CTLA-4 blockade-dependent changes. (A) Representative dot plots of 
CD45+ cell population. (B) Representative immunofluorescence images of CD45+ cells 
infiltrating intracranial tumors. (C) Percentages of CD45+ hematopoietic cells and CD3+ T cells 
as quantified by flow cytometry. Significant p values are summarized in Fig. S2B. (D-H) Analysis 
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of different T cell subpopulations (D), CD4+ Teff / Treg ratio (E), NK cells (F), 
CD11b+F4/80+CD45high macrophages (G) and CD11b+F4/80+CD45low microglia (H) within 
intracranial tumors by flow cytometry. Labeling as in D. All analyses were performed on day 12. 
Combined data from 3 independent experiments are shown (n=10/13/16/24 per group for CD45+, 
NK, microglia and macrophages; n=14/16/17/22 per group for T cell subpopulations). Significant 
differences were determined by $129$ZLWKDSRVWKRFWHVWSSS
S Detailed ANOVA parameters are provided in the Supplemental Table 1. 
 
Fig. 3. PD-1/CTLA-4 blockade- and extracranial disease-dependent molecular changes 
within intracranial B16 tumors. (A) Number of genes differentially expressed within intracranial 
tumors between experimental groups. (B) Unsupervised hierarchical clustering and heat map of 
top 2000 differentially expressed genes. (C-E) Unsupervised hierarchical clustering and heat maps 
of differentially expressed genes involved in NK cell function (C; the list of genes is based on the 
significantly enriched GO terms displayed on the left), T cell function (D; example genes are 
shown; heat map including all genes is given in Fig. S4B), and microglia (E). The analysis was 
performed on day 12. 
 
Fig. 4. CD8+ T cells and NK cells are required for intracranial efficacy of PD-1/CTLA-4 
blockade in B16 model. (A) Experimental timeline indicating administration of respective 
immune cell-depleting antibodies. (B-D) Survival analysis of anti-PD-1/anti-CTLA-4-treated mice 
bearing intracranial and extracranial tumors following in vivo depletion of CD4+ T cells, CD8+ T 
cells, or NK cells, respectively (n=16; pooled data from 2 independent experiments). Significant 
differences were determined with Log-rank test. P values shown are for comparison between the 
anti-PD-1/CTLA-4 group and the respective group in which a specific immune cell population has 
been depleted. 
 
Fig. 5. Anti-PD-1/anti-CTLA4 therapy in the context of extracranial disease potentiates 
trafficking of CD8+ T cells to intracranial B16 tumors. (A) Analysis of Ki67+ CD8+ T cells 
within intracranial tumors by flow cytometry. (B) Schematic representation of adoptive transfer 
experiments using CellTrace Violet (CTV)-labelled CD8+ T cells. (C) Representative dot plot of 
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adoptively transferred CTV+ CD8+ T cells detected within intracranial tumors. (D) Analysis of 
adoptively transferred CTV+ CD8+ T cells in intracranial tumors at 18 hours post-transfer (n=10). 
Labeling as in A. (E, F) Analysis of CD44+CD62L- CD8+ effector T cells in blood (E) and 
intracranial tumors (F) on day 12 (n=6/6/7/12 for blood; n=10/10 for intracranial tumors). Labeling 
as in A. (G) Dot plots of pooled spleen and lymph node cells isolated from donor mice for use in 
adoptive CD8+ T cell transfer experiments. Percentages of total CD8+ T cells and CD44+CD62L- 
cells within the CD8+ T cell population are indicated. (H) Representative dot plots of adoptively 
transferred CTV-tagged CD44+CD62L- (top) and CD44-CD62L+ (bottom) CD8+ T cells detected 
within intracranial tumors at 18 hours post-transfer. (I) Analysis of adoptively transferred CTV-
tagged CD44+CD62L- CD8+ T cells in intracranial tumors at 18 hours post-transfer (n=5). 
Significant differences in A and E were determined by ANOVA with a post hoc test, and in D, F 
and I with a two-tailed T-WHVWXQHTXDOYDULDQFHSSData from at least 2 
repeat experiments were pooled for analysis (A-F). Detailed ANOVA and T-test parameters are 
provided in Supplemental Table 1. 
 
Fig. 6. PD-1/CTLA-4 blockade upregulates vascular T cell trafficking determinants in 
intracranial B16 tumors. (A) Unsupervised hierarchical clustering and heat map of genes 
GLIIHUHQWLDOO\H[SUHVVHGZLWKLQWKH³/HXNRF\WHWUDQVHQGRWKHOLDOPLJUDWLRQ´.(**SDWKZD\)&
fold change; pval: p value. (B) Immunofluorescence staining for CD31 (endothelial cells) and 
VCAM-1 within intracranial tumors from treated mice bearing intracranial and extracranial 
tumors. (C) Representative dot plots of endothelial cells (CD45-CD31+) and ICAM-1 / VCAM-
1 staining within the endothelial cell population. (D) Analysis of ICAM-1 and VCAM-1 
expression in intracranial tumors by flow cytometry (n=5/5/7/9). One out of two representative 
experiments is shown. (E) Analysis RILQWUDFHOOXODU,)1ȖVWDLQLQJLQLQWUDFUDQLDOWXPRUVLVRODWHG
from Brefeldin A-WUHDWHGPLFHQ 3HUFHQWDJHRI,)1ȖFHOOVZLthin respective immune cell 
populations (top) and within total cell population (bottom) is shown. Data from two independent 
experiments were pooled for analysis. Significant differences in D and E-bottom were 
determined by ANOVA with a post hoc test, and in E-top with Mann-Whitney U Test (one-
WDLOHGSSSDetailed ANOVA parameters are provided in 
Supplemental Table 1. 






  
 
  
Suppelmentary methods 
Cell lines 
B16 F1 melanoma cells were obtained from the American Type Culture Collection (ATCC) and 
used between P4 and P8. B16/OVA cells were a kind gift from Prof. R. Vile, Mayo Clinic. OVA 
expression by this cell line was confirmed by qPCR. Ret melanoma cells (19, 29) were kindly 
provided by Dr. Neta Erez, Tel Aviv University. Mycoplasma test was performed routinely upon 
receipt of the cells and then every 6 months. All cell lines were tested for the presence of murine 
pathogens by IDEXX BioResearch (IMPACT IV PCR profile) and confirmed to be pathogen-free. 
B16 and B16/OVA FHOOVZHUHFXOWXUHGLQ'XOEHFFR¶VPRGLILHGHDJOHPHGLXP'0(06LJPD-
Aldrich) supplemented with 10% fetal bovine serum (FBS) (Gibco), 1x L-glutamine (Gibco) and 
1x penicillin streptomycin (Pen strep) (Gibco). Ret melanoma cells were cultured in RPMI-1640 
medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Gibco), 1x L-
glutamine (Gibco), 1x sodium pyruvate (Gibco) and 1x penicillin streptomycin (Gibco). For some 
experiments, cancer cells were stably transduced with Firefly luciferase-expressing lentiviral 
vector (25). 
 
Flow cytometry: antibody details 
Anti-CD3 (17A2), anti-CD8 (53-6.7), anti-CD8b (YTS156.7.7), anti-CD4 (GK1.5), anti-FoxP3 
(3G3), anti-CD49b (DX5), anti-Eomes (REA116), anti-CD69 (H1.2F3), anti-CD25 (7D4), and 
anti-MHCII (M5/114.15.2) were from Miltenyi. Anti-CD45 (30F11), anti-CD8b (53-5.8), anti-
NKp46 (29A1.4), anti-CD11b (M1/70), anti-NK1.1 (PK136), anti- ,)1Ȗ;0*DQWL-CD44 
(IM7), anti-CD62L (MEL-14), and anti-VCAM-1 (429 (MVCAM.A)) were from Biolegend. Anti-
Granzyme B (NGZB), anti-Ki67 (SolA15), anti-TIM-3 (RMT3-23), anti- 71)Į 03-XT22), 
anti-CD31 (390), and anti-ICAM1 (YN1/1.7.4) were from eBioscience. Anti-F4/80 was from AbD 
Serotec. 
 
Immunofluorescence 
Immunofluorescence was performed as previously described (25). Mice were perfused with saline 
and the isolated tissue was fixed in 4% paraformaldehyde for 24 hours. The tissue was cut into 10 
ȝPIUR]HQVHFWLRQVRQVOLGHV)ROORZLQJEORFNLQJZLWKJRDW serum in 0.03% Triton-X-100 / PBS, 
the sections were stained with anti-VCAM1 (clone MVCAM.A; Biolegend) and anti-CD31 (rabbit 
polyclonal; Abcam) antibody overnight, followed by fluorophore-conjugated secondary 
antibodies. Images were acquired with AxioImager Z1 fluorescence microscope equipped with 
AxioCam MRc5 digital camera using AxioVision Rel. 4.7 software (Zeiss). 
 
Adoptive transfer of CD8+ T cells 
Donor mice received two doses of anti-PD-1/CTLA-4 therapy or IgG, respectively, as specified. 
Cells from inguinal, axial, and mesenteric lymph nodes, and the splenocytes, were pooled and 
CD8+ T cells were isolated using CD8+ T cell isolation kit (Miltenyi). CD8+ T cells were labelled 
ZLWK&HOO7UDFH9LROHW7KHUPR)LVKHU6FLHQWLILFIROORZLQJPDQXIDFWXUHU¶VLQVWUXFWLRQVDQG[6 
cells were injected i.v. into recipient mice. The latter also received two doses of anti-PD-1/CTLA-
4 therapy or IgG, respectively, prior to adoptive T cell transfer, as specified under results. Tissue 
was analyzed by flow cytometry 18 hours post-adoptive transfer. 
For adoptive transfer of CD44+CD62L- and CD44-CD62L+ CD8+ T cell populations, total CD8+ 
T cells were isolated and labeled with CTV as described above, and subsequently stained with 
anti-CD8b, anti-CD44, and anti-CD62L antibodies. CD44+CD62L- and CD44-CD62L+ 
populations were isolated via facs using BD INFLUX cell sorter (BD Biosciences) and injected 
i.v. into recipient mice (treated as described above). We injected 1x105 CD44+CD62L- cells and 
2.4x106 CD44-CD62L+ cells per mouse. 
 
Isolation of RNA, generation of sequencing libraries, and mRNAseq 
Mice were perfused with saline. RNA from fresh tumor tissue (biological triplicates) was isolated 
using RNAqueous Total RNA Isolation kit (Ambion). Generation of sequencing libraries, mRNA 
sequencing and data analysis were performed by Novogene. A total amount of 3 µg RNA per 
sample was used as input material for RNA sample preparations. Sequencing libraries were 
JHQHUDWHGXVLQJ1(%1H[W8OWUD51$/LEUDU\3UHS.LWIRU,OOXPLQD1(%86$IROORZLQJ
PDQXIDFWXUHU¶V UHFRPPHQGDWLRQV DQG LQGH[ FRGHV ZHUH DGGHG WR DWWULEXWH VHTXHQFHV WR HDFK
sample. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. 
Fragmentation was carried out using divalent cations under elevated temperature in NEBNext First 
Strand Synthesis Reaction Buffer (5x). First strand cDNA was synthesized using random hexamer 
primer and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis was 
subsequently performed using DNA Polymerase I and RNase H. Remaining overhangs were 
converted into blunt ends via exonuclease/polymerase activities. After adenylation RI¶HQGVRI
DNA fragments, NEBNext Adaptor with hairpin loop structure were ligated to prepare for 
hybridization. In order to select cDNA fragments of preferentially 150~200 bp in length, the library 
fragments were purified with AMPure XP system (Beckman Coulter, Beverly, USA). USER 
Enzyme (NEB, USA) was used with size-selected, adaptor-ligated cDNA at 37°C for 15 min 
followed by 5 min at 95 °C before PCR. PCR was performed with Phusion High-Fidelity DNA 
polymerase, Universal PCR primers and Index (X) Primer. PCR products were purified (AMPure 
XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system.     
The clustering of the index-coded samples was performed on a cBot Cluster Generation System 
using TruSeq PE Cluster Kit v3-cBot-+6,OOXPLDDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
After cluster generation, the library preparations were sequenced on an Illumina Hiseq platform 
and 125 bp/150 bp paired-end reads were generated. 
 
Sequencing data analysis 
Data analysis was performed by Novogene. Quality control raw data (raw reads) in fastq format 
were firstly processed through in-house perl scripts. Clean data (clean reads) were obtained by 
removing reads containing adapter, reads containing poly-N and low quality reads from raw data. 
At the same time, Q20, Q30 and GC content of the clean data were calculated. All the downstream 
analyses were based on the clean data with high quality. 
To perform reads mapping to the reference genome, the reference genome and gene model 
annotation files were downloaded from the genome website directly. Index of the reference 
genome was built using Bowtie v2.2.3 and paired-end clean reads were aligned to the reference 
genome using TopHat v2.0.12. 
HTSeq v0.6.1 was used to count the reads numbers mapped to each gene (Quantification of gene 
expression level). FPKM of each gene was calculated based on the length of the gene and reads 
count mapped to this gene. FPKM, expected number of Fragments Per Kilobase of transcript 
sequence per Million base pairs sequenced, considers the effect of sequencing depth and gene 
length for the reads count at the same time, and is currently the most commonly used method for 
estimating gene expression levels (42). 
 
Differential gene expression analysis 
Differential expression analysis of two conditions/groups was performed using the DESeq R 
package (1.18.0). The resulting P-YDOXHV ZHUH DGMXVWHG XVLQJ WKH %HQMDPLQL DQG +RFKEHUJ¶V
approach for controlling the false discovery rate. Genes with an adjusted P-value found by DESeq 
were assigned as differentially expressed. 
 
GO and KEGG enrichment analysis of differentially expressed genes 
Gene Ontology (GO) enrichment analysis of differentially expressed genes was implemented by 
the GOseq R package, in which gene length bias was corrected. GO terms with corrected P-value 
less than 0.05 were considered significantly enriched by differential expressed genes. We used 
KOBAS software to test the statistical enrichment of differential expression genes in KEGG 
pathways (http://www.genome.jp/kegg/). 
 
Supplementary figure legends: 
Supplemental Figure 1. B16 melanoma tumor growth. (A) Growth curve of B16 melanoma s.c. 
tumors (n=8). (B) Growth curve of Firefly luciferase (Fluc)-tagged B16 melanoma intracranial 
tumors (B16/Fluc) as quantified by bioluminescence imaging (n=8). Fold change in 
bioluminescence signal intensity between the respective day and day 2 is shown (C) Statistical 
significance (p values) for the survival experiment shown in Fig. 1C. (D) Statistical significance 
(p values) for the survival experiment shown in Fig. 1F. (E) Representative images of B16/Fluc 
tumor-bearing brains. (F) Growth curve of Ret melanoma s.c. tumors (n=5). (G) Survival curves 
for mice bearing intracranial Ret/Fluc melanoma tumors following implantation of 1x103, 1x104 
and 1x105 cells, respectively (n=5). (H) Experimental time line for the implantation of cancer cells 
s.c. (Ret; 1x105) and intracranially (Ret/Fluc; 1x103), and the therapeutic schedule. The time line 
was determined based on s.c. and intracranial tumor growth shown in F and G.  
 
Supplemental Figure 2. Analysis of immune cell populations in intracranial B16/Fluc tumors 
by flow cytometry. (A) Gating strategy and representative contour plots for analysis of different 
immune cell populations. (B) Statistical significance (p values) for pair-wise comparison of 
percentages of CD45+ and CD3+ cells between experimental groups as determined by ANOVA 
ZLWKDSRVWKRFWHVW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Supplemental Figure 3. Quantification of immune cell populations within intracranial 
tumors. (A) Percentages of different immune cell populations within intracranial Ret/Fluc 
melanoma tumors following combined PD-1/CTLA-4 blockade or IgG treatment, as quantified by 
flow cytometry (n=7/5/6/7). (B) Percentages of different immune cell populations within 
intracranial B16/Fluc melanoma tumors following anti-PD-1 and anti-CTLA-4 monotherapies in 
comparison to IgG treatment, as quantified by flow cytometry (n=7). Significant differences were 
determined by $129$ZLWKDSRVWKRFWHVW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Supplemental Figure 4. Gene expression analysis (mRNAseq) of intracranial B16 tumors. 
(A) Unsupervised hierarchical clustering and heat map of differentially expressed genes involved 
in T cell function. (B) Unsupervised hierarchical clustering and heat map of differentially 
expressed genes related to macrophage function. 
 
Supplemental Figure 5. Depletion of specific immune cell populations in B16 model in vivo. 
Efficient depletion of CD4+ T cells, CD8+ T cells and NK cells, respectively, was confirmed in 
the blood (A) and within intracranial tumors (B) by flow cytometry. 
 
Supplemental Figure 6. Quantification of T cell activation/exhaustion markers in B16 model 
by flow cytometry. (A) Gating strategy and representative contour plots for analysis of different 
activation markers in CD8+ T cells by flow cytometry. (B) Quantification of marker expression in 
CD8+ T cells within intracranial tumors was performed by flow cytometry. Combined data from 
3 independent experiments are shown for CD25 and CD69 (n=13/16/17/22). Combined data from 
2 independent experiments are shown for all other markers (n=7/11/11/11). (C) Quantification of 
CD25 and CD69 expression in CD4+ T cells within intracranial tumors was performed by flow 
cytometry. Combined data from 3 independent experiments are shown (n=13/16/17/22). 
Significant differences in B and C were determined by ANOVA with a post hoc test. 
 
Supplemental Figure 7. Quantification of T cells in B16 model in the periphery. (A) Total 
number of cells and percentages of different T cell subpopulations in spleens were quantified by 
flow cytometry. Combined data from 2 independent experiments are shown (n=14/13/17/26). (B) 
Percentages of different T cell subpopulations in the blood were quantified by flow cytometry. 
Combined data from 2 independent experiments are shown (n=14/13/17/26). Significant 
differences were determiQHGE\$129$ZLWKDSRVWKRFWHVW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Supplemental Figure 8. Adoptive transfer of CD8+ T cells and upregulation of T cell homing 
determinants within B16 tumor microenvironment. (A) Percentages of CD8+ T cells within 
intracranial tumors were quantified by flow cytometry following 2 doses of anti-PD-1/anti-CTLA-
4 or IgG treatment (n=5). (B) Histograms of adoptively transferred CTV+ CD8+ T cells in the 
spleen and intracranial tumors at 18 hours post-transfer. (C) Quantification of ICAM-1+ and 
VCAM-1+ endothelial cells within intracranial tumors at an early time point following 2 doses of 
anti-PD-1/anti-CTLA-4 or IgG treatment (n=4). (D) Immunofluorescence staining for CD31 
(endothelial cells) and VCAM-1 within intracranial tumors in the experimental group receiving 
anti-PD-1/CTLA-4 treatment in the presence of extracranial disease. Tumor region (left) and 
adjacent brain parenchyma (right) are separated by a dotted line. Tumor blood vessels are positive 
for VCAM-1 staining (red arrows), while normal brain vessels show no VCAM-1 expression 
(white arrows). (E) 4XDQWLILFDWLRQRI,)1ȖH[SUHVVLRQZLWKLQLQWUDFUDQLDO WXPRUVE\P51$VHT
using biological triplicates. Fpkm: Fragments Per Kilobase of transcript sequence per Millions 
base pairs sequenced. (F) 4XDQWLILFDWLRQRI71)ĮH[SUHVVLRQZLWKLQLQWUDFUDQLDOWXPRU-infiltrating 
immune cells by intracellular flow cytometry. Significant differences in A and D were determined 
E\$129$ZLWKDSRVWKRFWHVWS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Supplemental Table 1. Top: ANOVA parameters. F value, degrees of freedom (DF), and p 
values are shown for the data that have been analyzed by ANOVA. The figure number for each 
data set is specified in the first column. Bottom: T-test parameters. T-value, degrees of freedom 
(DF), and p value are shown for the data that have been analyzed by T-test. The figure number 
for each data set is specified in the first column. 
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ANOVA parameters 
Figure Parameter  F value 
DF (between 
columns) 
DF (within 
columns) DF (Total) p value 
2C CD45 16.31 3 68 71 <0.0001 
2C CD3 13.98 3 65 68 <0.0001 
2D CD8 15.19 3 64 67 <0.0001 
2D CD4 13.27 3 34 37 <0.0001 
2D CD4 Tregs 15.00 3 34 37 <0.0001 
2D CD4 Teff 9.15 3 34 37 0.0001 
2F NK 0.44 3 66 69 0.7285 
2G Macrophages 6.99 3 68 71 0.0004 
2H Microglia 5.10 3 68 71 0.003 
5A Ki67 1.452 3 36 39 0.2438 
5E CD44+CD62L- (blood) 28.69 3 27 30 <0.0001 
6D ICAM1 (%) 20.91 3 22 25 <0.0001 
6D VCAM1 (%) 60.66 3 22 25 <0.0001 
6D ICAM1 (MFI) 47.45 3 22 25 <0.0001 
6D VCAM1 (MFI) 30.92 3 22 25 <0.0001 
 
 
T-test parameters 
Figure Parameter  t-value df p value 
5F CD44+CD62L- (Intracr. T) 1.33 4.77 0.2422 
5C CTV+CD8+ T cells 6.78 9.26 <0.0001 
 
Table S1 
